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Abstract
Insufficient calcium intake has been proposed to cause unbalanced energy partitioning leading to obesity.
However, weight loss interventions including dietary calcium or dairy product consumption have not reported
changes in lipid metabolism measured by the plasma lipidome.
Methods: The objective of this study was to determine the relationships between dairy product or supplemental
calcium intake with changes in the plasma lipidome and body composition during energy restriction. A secondary
objective of this study was to explore the relationships among calculated macronutrient composition of the energy
restricted diet to changes in the plasma lipidome, and body composition during energy restriction. Overweight
adults (n = 61) were randomized into one of three intervention groups including a deficit of 500kcal/d: 1) placebo;
2) 900 mg/d calcium supplement; and 3) 3-4 servings of dairy products/d plus a placebo supplement. Plasma fatty
acid methyl esters of cholesterol ester, diacylglycerol, free fatty acids, lysophosphatidylcholine, phosphatidylcholine,
phosphatidylethanolamine and triacylglycerol were quantified by capillary gas chromatography.
Results: After adjustments for energy and protein (g/d) intake, there was no significant effect of treatment on
changes in weight, waist circumference or body composition. Plasma lipidome did not differ among dietary
treatment groups. Stepwise regression identified correlations between reported intake of monounsaturated fat (%
of energy) and changes in % lean mass (r = -0.44, P < 0.01) and % body fat (r = 0.48, P < 0.001). Polyunsaturated
fat intake was associated with the % change in waist circumference (r = 0.44, P < 0.01). Dietary saturated fat was
not associated with any changes in anthropometrics or the plasma lipidome.
Conclusions: Dairy product consumption or calcium supplementation during energy restriction over the course of
12 weeks did not affect plasma lipids. Independent of calcium and dairy product consumption, short-term energy
restriction altered body composition. Reported dietary fat composition of energy restricted diets was associated
with the degree of change in body composition in these overweight and obese individuals.
Background
Chronic unfavorable alterations in metabolic regulation
eventually lead to life-threatening diseases characterized
symptomatically by abdominal obesity, dyslipidemia,
hypertension, insulin resistance, type 2 diabetes, and
coronary artery disease [1]. Metabolic dysregulation and
its consequences have been assigned to genetic predis-
positions combined with environmental and dietary fac-
tors that in some individuals lead to unbalanced energy
intake and expenditure. Diet, both essential and nones-
sential nutrients may play a role in metabolic regulation
[2]. Particular studies suggest that insufficient calcium
intake is associated with unbalanced lipid metabolism in
children and adults [3-5]. Mean dietary intakes of cal-
cium in the US adult population are below the adequate
intake values [6] and milk intake has also decreased
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domized clinical studies demonstrate significant inverse
associations between calcium [8-12] and dairy product
intake [7,8,10,13], and both body fat (BF) mass and body
weight. During energy restriction, calcium supplementa-
tion augmented weight and BF losses compared with
the control group without supplementation [4,5]. Yet,
dairy product consumption accelerated weight and BF
losses to a greater degree than supplemental calcium
[3]. How dairy composition and structure modulates
lipid metabolism is not well understood.
Lipid metabolism can be estimated by accurate mea-
sures of tissue lipid metabolites in which concentrations
of substrates and products reflect entire biochemical
pathways [14]. Tissue and circulating lipidome reflect
genetics [15], diet [16-20], lipid metabolism [21-25],
stress [26] and endocrine activity [24]. Several plasma
lipid metabolites are maintained normally within narrow
concentrations. Measured deviations from normal
ranges are being recognized as diagnostic indices for
both early and late stages of metabolic dysregulation.
For example, elevated concentrations of serum total free
fatty acids (FFA), and of palmitic acid (16:0) in particu-
lar are associated with insulin resistance in peripheral
tissues including muscle, liver, and pancreas [27]. More-
over, independent prospective case-cohort studies have
found that the incidence of type 2 diabetes was posi-
tively associated with the proportions of plasma palmitic
(16:0) and stearic acid (18:0) in middle aged men and
women [28,29]. In overweight otherwise healthy indivi-
duals, baseline circulating phosphatidylcholine (PC) stea-
r i ca c i d( 1 8 : 0 ) ,a n dF F A1 8 : 1 ( n - 9 )e x p l a i n e d2 0 - 3 0 %o f
the variance for changes in body composition during
energy restriction in those individuals that lost weight
[25]. Use of quantitative lipidomics led to the identifica-
tion of plasma palmitoleate (16:1n7) as an adipose tis-
sue-derived lipid hormone that strongly stimulated
muscle insulin action and suppressed hepatosteatosis in
adipose tissue lipid chaperone aP2 and mal1 deficient
mice [24]. The primary aim of this of this study was to
determine the relationship between dairy product or
supplemental calcium intake and changes in the plasma
lipidome and body composition of overweight and obese
individuals during energy restriction. An additional aim
examined associations between reported compositions
of energy restricted diets independent of treatment
group, plasma lipidome measurements and changes in
anthropometrics.
Methods
Subjects
In the parent project 105 overweight and mildly obese
individuals were recruited from the faculty, staff, and
student populations of each of the three participating
institutions (University of Tennessee, Purdue University,
and the USDA, ARS, Western Human Nutrition
Research Center at the University of California, Davis).
S e v e n t yn i n es u b j e c t sc o m p l e t e dt h et r i a la n d6 3m e t
the parent study’s a priori weekly compliance criteria
[30], however due to missing measurements, the major-
ity of data are reported for 61 subjects. Intent-to-treat
analysis was not conducted because there were only two
time points: baseline and 12 weeks. Subjects were
included in the study if they were: 18-35 years of age,
h a da ni n i t i a lB M Io f2 5 - 3 4 . 9k g / m
2,c o n s u m e dal o w -
calcium diet at enrollment (< 600 mg calcium/d) from
non-calcium-fortified foods and < 800 mg total calcium/
d, did not gain or lose more than 3 kg of body weight
during the past three months, and did not recently (4
wk) change exercise intensity or frequency. Subjects
were excluded from participation of the study if they
smoked; required the use of oral anti-diabetic agents or
insulin; used obesity pharmacotherapeutic agents and/or
herbal or other preparations intended for use in obesity
or weight management within the previous 12 wk; used
calcium supplements within the previous 12 wk; had a
history of significant endocrine, hepatic, or renal disease;
were pregnant or lactating; had a recent (past 12 wk)
initiation of or change in oral contraceptive; suffered
any active form of malabsorption syndrome; or had a
history of eating disorders. The project was approved by
the Institutional Review Board of each of the three par-
ticipating institutions. Written informed consent was
obtained from all subjects, and the research was con-
ducted in accordance with the ethical standards outlined
in the Helsinki Declaration.
Study Protocol
This study was designed to determine whether dairy
products or calcium supplementation would accelerate
weight and fat loss induced by energy restriction in
otherwise healthy overweight and obese adults. After
enrollment, subjects were studied for a 2-wk lead-in per-
iod to establish their current energy requirements and
provide an opportunity for baseline dietary and physio-
logical assessment, and then randomized to the follow-
ing dietary regimens for 12 wk: 1) a control diet
providing a 2093 kJ/d deficit (500 kcal/d), 0-1 serving of
dairy products/d, 500 mg calcium/d, and a daily placebo
supplement; 2) a calcium-supplemented diet identical to
the control diet, with the placebo replaced by 900 mg
calcium in the form of calcium carbonate; or 3) a high-
dairy diet (placebo-supplemented) providing a 2093 kJ/d
deficit (500 kcal/d) and containing three daily servings
dairy products (milk, cheese, and/or yogurt) to bring the
total calcium intake from 500 to 1400 mg/d. The cal-
cium supplemented and placebo arms of the study were
conducted in a placebo-controlled, blinded fashion, and
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ever, subjects on the high-dairy diet also received a pla-
cebo supplement and all groups were treated as active-
treatment arms, with pill counts serving as a compliance
measurement.
Diets
Following instructions from a trained nutritionist during
the 2-wk lead-in period, baseline 7-d dietary records
were completed by each subject and reviewed for com-
pleteness by the project dietitian at each site. Diet
records were analyzed by Nutritionist Pro software and
were used to provide an initial estimate of an energy
intake. The estimate of energy intake was then refined
by calculating energy needs using World Health Organi-
zation equations for calculating basal metabolic rate,
adjusted for Physical Activity Level (PAL) set at low-
active (1.4) to provide an estimate of total daily energy
expenditure, and reported elsewhere [31]. Based on this
initial estimate of energy needs, a food exchange-based
diet was prescribed to produce an energy deficit of
approximately 2093 kJ/d. The diets for the treatment
arms were constructed to provide comparable levels of
macronutrient and fiber, to approximate the average
consumption in the U.S. (fat, ~35% of total energy, car-
bohydrates ~49%, ~protein 16%, fiber 2-3 g/1,000 kJ/
day). Nutritional supplements were not permitted, and
caffeine intake was maintained at a constant level (indi-
vidualized for each patient, based on baseline assess-
ment). Diets were prescribed and monitored as noted
above. Subjects in the high dairy group were permitted
to utilize both full-fat and low-fat milk, cheese and
yogurt, with the fat accounted for in exchange lists
given with each individual diet prescription. Subjects
were provided individual instruction, counseling, and
assessment from the study dietitian regarding dietary
adherence and the development and reinforcement of
strategies for continued success. Subjects maintained
daily food records throughout the 12 wk intervention
period, and compliance was assessed by weekly subject
interview and review of the diet diary and pill counts.
Compliance criteria are reported elsewhere [30,31].
Nutrient assessment was computed by averaging 7-d
diet records for the 2-wk run-in period with each day of
the week represented twice. During the intervention
weeks 0-11, subjects filled out 7-day diet records but
nutrient intake was assessed from averaging data from 3
of the 7 days (2 progressive weekdays and 1 weekend).
The 3 day selection from each week (0-11) started with
the first weekday and alternated between Saturday and
Sunday. Each 3 days rotated through the week such that
by the end of the 12wk intervention, a total of 36 days
were included with each day of the week counted 3
times. For example, during week 0, nutrient intake data
were selected from Monday, Tuesday, and Saturday and
during week 1, nutrient intake data were selected for
Wednesday, Thursday and Sunday. Nutrient analysis
was completed using Nutritionist Pro Food Processor
Plus software. Baseline micro- and macronutrient
intakes were determined by averaging the pooled nutri-
ent data from the 2-wk run-in period. Micro- and
macronutrient intake during the 12 wk intervention per-
iod was determined by averaging the pooled nutrient
data from weeks 2-11. Data were not included for base-
line or week 1 to allow subjects a 2-wk adaptation per-
iod to accurately log dietary intake data.
Anthropometric measurements
Measurement of body weight was done during the 2-wk
run-in period and weekly thereafter; height was mea-
sured at baseline, and waist circumference (WC) at
baseline and 12 wk. BMI was calculated as kg/m
2. Total
fat and lean mass (LM) were assessed via dual energy
X-ray absorptiometry (Lunar Prodigy instrument; GE
Medical Instruments) at baseline and week 12 of the
study. Statistical models were developed to predict the
following anthropometric outcomes: 1) percent change
in weight; 2) percent change in WC; 3) percent change
in % LM and 4) percent change in % body fat (BF).
Physical activity assessment
Participants were instructed not to change their usual
physical activity habits during the study and to ensure
that physical activity remained unchanged; 3-d physical
activity records were collected from all subjects at base-
line and week 12. Participants were asked to report any
changes to their usual physical activity.
Metabolite measurements
Plasma glucose, TG, LDL cholesterol, and HDL choles-
terol were measured at each site’s clinical medical
laboratory with a Beckman Lxi-725 auto-analyzer. Fast-
ing plasma insulin was measured using a commercially
available radioimmunoassay kit (Linco Research, St.
Charles, MO) at each site’s clinical medical laboratory.
Insulin resistance at baseline and 12 wk was calculated
using the Homeostasis Model Assessment (HOMA-IR)
[32].
Analysis of the plasma lipidome
Blood was collected from all participants into evacuated
tubes containing EDTA, centrifuged immediately (1300
× g, 10 min, 20°C), portioned into aliquots, and stored
at -80°C until analyzed. Fatty acid analyses of circulating
lipid classes were measured by high-throughput meth-
ods developed by Lipomics Technologies, Inc. (West
Sacramento, CA) [33]. In brief, the lipids from plasma
(200 μl) were extracted using a modified Folch
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extraction was performed in t h ep r e s e n c eo fap a n e lo f
quantitative authentic internal standards. Extracted
lipids were dried under N2 gas for for separation by
chromatography. Individual phospholipid classes within
the extract were separated by high performance liquid
chromatography [24]. Individual neutral lipid classes
were separated from the extract by thin layer chromato-
graphy. Each separated lipid class was collected and
dried under nitrogen in preparation for trans-esterifica-
tion. Lipid classes were trans-esterified in 3 N methano-
lic HCl in sealed vials under a nitrogen atmosphere at
100°C for 45 min. The resulting fatty acid methyl esters
were extracted from the mixture with hexane and pre-
pared for automatic injection into a gas chromatograph
by sealing the hexane extracts under nitrogen. Fatty acid
methyl esters were separated and quantified by capillary
GC using an Agilent 6890 gas chromatograph equipped
with a 30-m DB-88 capillary column (Agilent Technolo-
gies, Santa Clara, CA) and a flame-ionization detector.
Fatty acids of each lipid class were determined quantita-
tively (μmol/L) and expressed as a percentage of total
fatty acids within that class (mol %). Total lipid classes
were calculated as the sum of individual fatty acid spe-
cies for each lipid class fraction. Fatty acids with missing
values at 20% or greater were dropped from the analyses
and considered not determined (ND).
Statistical analyses
All statistical procedures were conducted using SPSS
version 16 for Windows (SPSS, Chicago, IL). Means ±
SD are reported for baseline and 12 wk anthropometric
measurements; reported macro- and micronutrient
intake; circulating plasma clinical metabolites; circulat-
ing total lipid classes; and fatty acid composition of cir-
culating cholesterol ester (CE), free fatty acids (FFA),
phosphatidylcholine (PC), and triacylglycerol (TG). All
data were examined for normality and transformed as
needed prior to conducting statistical analyses. Repeated
Measures ANOVA was performed to determine the
effect of time, treatment and time x treatment on
anthropometric outcomes, dietary intake and circulating
lipids. If repeated measures ANOVA demonstrated a
significant time effect between baseline and 12 wk vari-
ables, a paired sample two-tailed t-test was performed
to identify the treatment group that reached signifi-
cance. ANCOVA was performed to determine differ-
ences between treatment groups for both baseline and
12 wk circulating lipid metabolites, clinical metabolites,
dietary intake, and anthropometric measurements. Mul-
tiple comparisons analysis with a Bonferroni adjustment
was used to determine differences among the three
treatment groups. Final models on dietary intake were
adjusted for site, sex, and energy intake at 12 wk.
Models for dependent variables that already included
energy in their calculations–Protein, SFA, MUFA and
PUFA (% of energy)–were not adjusted for 12wk energy
intake. Stepwise regressions were generated to explore
the relationships between 12 wk dietary fat composition
and 12 wk circulating lipids of the same family (i.e.,
dietary saturated fat against circulating saturated fatty
acids). Details of the criteria followed to generate step-
wise regressions are reported elsewhere [25]. Stepwise
regressions were also used to examine the relationships
among 12 wk diet composition; plasma clinical biomar-
kers; and lipid metabolites with changes in anthropo-
metrics. The three treatments and sites were converted
into two orthogonal variables for use in linear regres-
sion. For each stepwise regression, the F statistic prob-
ability was set at an alpha between 0.01 and 0.05.
Normality for each stepwise regression model was deter-
mined by generating normal probability plots of the
regression standardized residual. Equal variance for each
regression model across each dependent variable was
determined by plotting the standardized predicted
dependent variable by the standardized residuals. Outly-
ing cases that strongly influenced each stepwise regres-
sion model were tested by Cook’sd i s t a n c e( D ) .D a t a
points with larger D values than the rest of the data
were considered highly influential and deleted. The
models with deleted observations with large D values
were re-regressed and compared to ensure the model
was statistically relevant and not a product of one highly
influential data point. Multi-collinearity between base-
line lipids selected by stepwise regression was checked
by a Variance Inflation Factor of ≤ 2.0. If variables
demonstrated a Variance Inflation Factor greater than
2.0, they were dropped from the final regression model.
The following stepwise regressions were generated:
reported intake of % saturated fat (SFA) (% of fat) at 12
wk as a dependent variable and 12 wk circulating
plasma 14:0, 15:0, 16:0, and 18:0 of each lipid class as
independent variables; reported intake of % monounsa-
turated fat (MUFA) (% of fat) at 12 wk as a dependent
variable and 12 wk circulating plasma 16:1(n-7), 18:1(n-
7), 18:1(n-9) of each lipid class as independent variables;
and reported intake of % polyunsaturated fat (PUFA) (%
of fat) 12 wk as a dependent variable with 12 wk circu-
lating plasma 18:2(n-6), 18:3(n-6), 20:3(n-6), 20:4(n-6),
18:3(n-3), 20:5(n-3), and 22:6(n-3) of each lipid class as
independent variables. Stepwise regressions were also
generated to determine the relationships between 12 wk
dietary fat composition (SFA, MUFA, and PUFA) as a
percent of energy and changes in body composition.
For each statistical analysis, only fatty acids for each
lipid class with mean abundances of 1.0% or greater
were analyzed. Estimation of desaturase and elongase
enzymatic activities involved in fatty acid metabolism as
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ratios of circulating 16:1(n-7)/16:0 and 18:1(n-9)/18:0
were used as surrogates for delta 9-desaturase activity;
the ratios of 18:3(n-6)/18:2(n-6) and 20:4(n-6)/20:3(n-6)
were used as surrogates for delta 6- and delta 5-desatur-
ase activity, respectively; and the ratios of 18:1(n-7)/16:1
(n-7), 18:0/16:0, and 20:2(n-6)/18:2(n-6) were used as
surrogates for elongase activities [35].
F a t t ya c i dd a t aw e r eo n l ya v a i l a b l ef o r6 1s u b j e c t s ;
total lipid class data for 60 subjects; and plasma glucose,
HOMA-IR and waist circumference at 12 wk were only
available for 59 subjects and reported herein. ANCOVA
and regressions used to determine relationships between
any independent variable and change in anthropometrics
were adjusted for site, age, sex, energy, protein (g/d)
intakes and physical activity at 12 wk and baseline
HOMA-IR.
Results
Anthropometric measurements at baseline and 12 wk for
dairy, calcium, and placebo groups
Nineteen females and four males completed the dairy
intervention, seventeen females and two males com-
pleted the calcium supplemental intervention, and
twenty females and six males completed the placebo
intervention (Table 1). There were no reported changes
in physical activity during the study period and no sig-
nificant differences for age, baseline weight, % LM, and
% BF and WC among the treatment groups (data not
shown). There were significant differences in the mean
age (P < 0.0005), weight (P < 0.05), BMI (P < 0.05),
waist circumference (P < 0.01), intakes of calcium (P <
0.05) and SFA (% of energy) (P < 0.01) at baseline and
attrition rates (P < 0.0005) among the sites (data not
shown). There were significant in reductions in weight,
% BF, waist circumference, plasma insulin and HOMA-
IR and an increase in % LM for all treatment groups at
the end of the intervention (Table 1). The mean percent
change in any anthropometric measurement was not
significantly different among treatment groups after
adjustments for dietary intake of protein, energy, and
physical activity (data not shown).
Mean dietary intake at baseline and 12 wk for dairy,
calcium, and placebo groups
Total energy intake was significantly reduced from
baseline for all treatment groups, yet the dairy group
consumed about 15% more energy than the placebo
and calcium groups (Table 2). In addition, the amount
of protein (g/d) was reduced by 30% from baseline to
12 wk for the placebo and calcium groups, yet there
was no difference for the dairy group (data not
shown). Total dietary fat (% of energy) decreased from
baseline to 12 wk for all of the treatment groups but
the fat composition varied among the treatment
groups. Intake of SFA (% of fat and energy) remained
unchanged between baseline and 12wk for the dairy
group but decreased for the calcium and placebo
groups. The dairy group consumed approximately 25%
higher saturated fat (% of fat) compared with the cal-
cium and placebo groups. Intake of MUFA (% of fat)
increased from baseline to 12 weeks for the calcium
Table 1 Anthropometric and clinical measurements of study participants at baseline and 12 wk for each treatment
group
1
Dairy (n = 22 ) Calcium (n = 16) Placebo (n = 23)
Characteristic Baseline 12 wk Baseline 12 wk Baseline 12 wk
Age (y) 25.1 ± 5.3 25.2 ± 4.9 24.2 ± 4.7
Sex, No.(%)
Female 18 (82) 14 (88) 18 (78)
Male 4 (18) 2 (13) 5 (22)
Height (cm) 166.9 ± 6.0 164.6 ± 9.0 166.1 ± 7.6
Glucose (mmol/L)
2,3 4.6 ± 0.4 4.6 ± 0.4 4.8 ± 0.4 4.8 ± 0.5 4.8 ± 0.5 4.8 ± 0.4
Insulin (pmol/L)
2 42.5 ± 28.5 33.5 ± 29.0** 41.8 ± 26.2 35.1 ± 21.1** 35.7 ± 14.7 29.9 ± 10.3**
HOMA-IR
2,3 1.3 ± 0.9 1.0 ± 0.9** 1.3 ± 0.9 1.1 ± 0.8** 1.1 ± 0.5 0.9 ± 0.3**
Weight (kg)
2 79.1 ± 12.1 74.8 ± 10.4** 79.2 ± 12.6 75.8 ± 10.6** 79.7 ± 11.7 76.5 ± 11.2**
BMI
2 28. 3 ± 3.0 26.7 ± 2.5** 29.1 ± 2.7 28.1 ± 2.6** 28.8 ± 2.7 27.7 ± 2.8**
LM (%)
2 54.5 ± 5.9 57.9 ± 6.6** 58.3 ± 6.6 58.7 ± 7.0** 55.0 ± 5.9 56.9 ± 5.9**
BF (%)
2 41.2 ± 5.7 37.7 ± 6.5** 37.6 ± 6.2 36.0 ± 6.7** 40.9 ± 5.2 38.8 ± 5.2**
WC (cm)
2,3 88.9 ± 9.6 81.1 ± 8.6** 88.1 ± 9.2 83.3 ± 7.5** 87.4 ± 11.8 82.6 ± 11.3**
1Data are means ± SD; n = 61 unless otherwise indicated. WC, waist circumference; LM, lean mass. There were no significant differences in baseline
anthropometrics or plasma metabolites among treatment groups (ANOVA).
2Repeated Measures ANOVA to test the effect of time; confirmed with paired sample t-test for significant differences between baseline and 12 wk, *P < 0.01, **P
< 0.001, There was no significant effect of time or time x treatment interaction.
3n = 59.
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dairy group. The calcium and placebo groups con-
sumed approximately 18% more monounsaturated fat
(% of fat) compared with the dairy group. Intake of
PUFA (% of fat and energy) remained unchanged
between baseline and 12 wk among the treatment
groups, however the calcium and placebo groups con-
sumed approximately 24% more PUFA (% of fat) than
the dairy group. The dairy group consumed fat with
significantly lower n6:n3 compared with the calcium
and placebo groups; however this relationship disap-
peared after adjustments for site, sex and energy. In
addition to the macronutrien t s ,t h e r ew e r es i g n i f i c a n t
differences for reported mean micronutrient intakes
among the treatment groups. Reported dietary intakes
of biotin, pantothenic acid, riboflavin, vitamin B12 and
vitamin D were significantly higher in the dairy com-
pared with the calcium and placebo groups. In addi-
tion, the dairy group reported greater intake of
c a l c i u mb y2 0 %a n d1 . 8 - f o l dc o m p a r e dw i t ht h ec a l -
cium and placebo groups, respectively; and the calcium
group reported a 1.3 fold higher intake of calcium
compared with the placebo group. There were no sig-
nificant differences among treatment groups for % car-
bohydrates (of energy), cholesterol, thiamin, and
vitamin B6 (Table 2).
Clinical metabolites and total lipid classes at baseline and
12 wk
There were no significant time, treatment, or time x treat-
ment effects for total cholesterol, or LDL and HDL choles-
terol (data not shown) and total lipid classes (Table 3).
There were significant treatment x time interactions for
total circulating CE and total FFA (data not shown) due to
higher plasma baseline total CE and FFA for the dairy but
not calcium or placebo groups despite subject randomiza-
tion into treatment groups at enrollment. However, after
adjustments for age, site, sex, HOMA-IR and physical
Table 2 Mean daily dietary intake at baseline and during the study (12 wk) for each treatment group
1
Dairy (n = 22) Calcium (n = 16) Placebo (n = 23)
Nutrient Baseline 12 wk Baseline 12 wk Baseline 12 wk
Total energy (kcal/d)
2,4 2122 ± 630 1510 ± 225*
,a 1910 ± 415 1300 ± 200* 1960 ± 500 1300 ± 200*
Energy (kJ/d) 8880 ± 2640 6340 ± 940 8000 ± 1740 5460 ± 850 8200 ± 2100 5440 ± 825
Carbohydrate (% EN) 51.8 ± 7.8 50.9 ± 5.4 48.7 ± 4.6 51.0 ± 4.8 52.6 ± 6.2 53.6 ± 5.2
Protein (% EN)
2^
,4 14.0 ± 2.5 19.0 ± 1.8*
,a 15.1 ± 2.5 17.4 ± 2.1*
,b 14.4 ± 3.0 16.7 ± 2.5*
,b
Fat (% EN) 31.8 ± 5.1 28.1 ± 4.7* 35.3 ± 4.9 30.1 ± 3.9* 31.9 ± 5.1 28.2 ± 4.7*
SFA (% fat)
2^
,4 49.9 ± 5.8 50.5 ± 6.2
a 44.9 ± 5.9 41.1 ± 3.6*
,b 46.4 ± 5.0 41.3 ± 3.9*
,b
SFA (%EN)
2g,4 11.0 ± 2.8 11.5 ± 2.9
a 11.8 ± 1.9 9.8 ± 1.5*
,ba 10.3 ± 2.3 9.2 ± 1.8
b
MUFA (% fat)
2g,4 32.5 ± 3.8 31.7 ± 4.0
a 33.9 ± 4.1 36.9 ± 3.0*
,b 34.0 ± 3.5 37.6 ± 2.6*
,b
MUFA (%EN)
3,4 7.2 ± 2.1
a 7.2 ± 1.5
a 9.0 ± 2.0
b 8.8 ± 1.3
b 7.6 ± 2.1
ab 8.5 ± 1.9
b
PUFA (% fat)
4 17.6 ± 4.9 17.7 ± 3.5
a 21.2 ± 5.6 22.0 ± 2.8
b 19.6 ± 4.0 21.0 ± 2.9
b
PUFA (%EN)
4 3.8 ± 1.3
a 4.0 ± 0.8
a 5.7 ± 2.0
b 5.2 ± 0.8
b 4.3 ± 1.1
ab 4.7 ± 1.0
b
n6:n3 ratio
2,g,4 8.9 ± 3.3 6.6 ± 3.1* 8.8 ± 3.8 8.7 ± 2.5 10.7 ± 5.5 7.9 ± 2.8*
Cholesterol (mg/d) 214.3 ± 97.0 182.4 ± 64.1 239.0 ± 128.9 148.7 ± 43.8* 207.1 ± 104.3 152.2 ± 54.1*
Biotin (μg/d)
2^
,4 8.3 ± 5.9 16.1 ± 5.7*
,a 8.2 ± 3.9 8.5 ± 4.7
b 9.9 ± 6.4 9.9 ± 5.1
b
Calcium (mg/d)
2^
,4 772.3 ± 243.4 1244.8 ± 108.0*
,a 644.0 ± 122.4 1035.1 ± 72.3*
,b 711.7 ± 202.6 449.0 ± 69.7*
,c
Niacin (mg/d) 15.9 ± 6.0 13.9 ± 3.8 15.0 ± 5.3 15.4 ± 4.8 15.4 ± 3.7 15.3 ± 5.2
Pantothenic acid (mg/d)
2^
,4 2.3 ± 1.1 3.41 ± 0.7*
,a 2.2 ± 0.9 2.1 ± 0.71
b 2.2 ± 0.9 2.4 ± 0.9
b
Riboflavin (mg/d)
2^
,4 1.3 ± 0.4 1.76 ± 0.3*
,a 1.2 ± 0.4 0.95 ± 0.3
b 1.3 ± 0.3 1.1 ± 0.3*
,b
Thiamin (mg/d) 1.2 ± 0.35 1.1 ± 0.3 1.0 ± 0.3 1.0 ± 0.5 1.2 ± 0.4 1.1 ± 0.4
Vitamin B6 (mg/d) 1.2 ± 0.5 1.3 ± 0.4* 1.2 ± 0.5 1.3 ± 0.5 1.1 ± 0.3 1.4 ± 0.6*
Vitamin B12 (μg/d)
2^
,4 2.7 ± 1.7 3.8 ± 1.7*
,a 3.2 ± 1.8 2.2 ± 1.0*
,b 2.2 ± 1.1 2.3 ± 1.4
b
Vitamin D (μg/d)
2^
,4 1.8 ± 1.1 4.8 ± 2.1*
,a 1.8 ± 0.7 0.9 ± 0.8*
,b 1.9 ± 1.3 1.1 ± 0.8*
,b
1 Data are means ± SD; n = 61. EN, energy; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
2Repeated measures ANOVA was performed to test the effect of time; time x treatment and treatment, confirmed with paired sample t-test was for significant
differences between baseline and 12 wk. Time, *P < 0.05; time x treatment, ^P < 0.01,
gP < 0.05.
3ANCOVA to test the effect of treatment on reported baseline nutrient intake with adjustments for reported site, sex and baseline energy intake. The final models
were not adjusted for baseline energy intake because the dependent variables –MUFA and PUFA as a percent of energy are already adjusted for energy intake.
Pairwise comparisons with Bonferroni adjustment was used to determine differences among treatments. Values with different superscript letters are significantly
different; P < 0.05.
4ANCOVA to test the effect of treatment on reported 12 wk nutrient intake with adjustments for site, sex, and energy intake at 12 wk. Protein, SFA, MUFA and
PUFA as a percent of energy were not adjusted for energy intake. Pairwise comparisons with Bonferroni adjustment was used to determine differences among
treatments. Values with different superscript letters are significantly different. P < 0.05.
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Page 6 of 10activity at baseline, total CE at baseline was no longer sig-
nificantly different for the dairy group.
Relationships between reported dietary fat intake as a
percent of total fat and plasma lipidome
There was no significant time, treatment or time x treat-
ment effects for any plasma fatty acids of CE, FFA, PC
or TG. There were no significant relationships among
reported intakes of MUFA and circulating lipid species
at baseline. There was a significant relationship between
reported intake of MUFA (% of fat) and circulating
plasma CE 18:1(n-9) at 12 wk (partial r = 0.33, P <
0.05), however this relationship disappeared when the
model was adjusted for sex. Reported intake of % SFA
and % PUFA were not associated with circulating SFA
or PUFA lipid species at baseline or 12 wk, respectively.
Relationships between reported fat intake as a percent of
total energy and body composition
Final models for the relationships among reported fat
intake and body composition are displayed in Table 4.
Reported mean dietary intake of % MUFA at 12 wk was
inversely associated with the change in % LM (partial r
= -0.44, P < 0.01) (Figure 1A) and positively associated
Table 3 Circulating total lipid classes of study
participants at baseline and 12 wk
1
Lipid (nmol/mL)
Lipid class Baseline 12 wk
Cholesterol ester 3,850 ± 870 3,770 ± 830
Diacylglycerol 69.3 ± 27.5 65.6 ± 33.0
Free fatty acid 600 ± 250 540 ± 190
Lysophosphatidylcholine 170 ± 47.0 160 ± 39.0
Phosphatidylcholine 1,470 ± 350 1,500 ± 400
Phosphatidylethanolamine 185 ± 120 180 ± 100
Triacylglycerol 1,130 ± 560 1,060 ± 500
1Data are means ± SD; n = 60.
Table 4 Final models for the relationships between
dietary fat intake (% of energy) and changes in body
composition at 12 wk
1
Anthropometrics Dietary
Intake
Model
R
Adjusted
R
2
Model <
P
LM change (%) MUFA 0.59 0.24 0.01
BF change (%) MUFA 0.63 0.30 0.01
WC change (%)
2 PUFA 0.69 0.38 0.001
1 Stepwise regression (n = 61) was used to determine relationships between
reported dietary fat intake and changes in body composition. Dependent
variables included changes in anthropometrics and independent variables
included reported intakes of SFA, MUFA and PUFA (% of energy). Final models
were adjusted for site, sex, age, energy, protein (g/d), physical activity at 12 wk;
and HOMA-IR at baseline. LM, lean mass; BF, body fat; WC, waist circumference.
2 n=5 9
A. 
 
B. 
 
C.        
r
 =-0.44, P < 0.01 
r
 = 0.45, P < 0.001 
r
 = 0.49, P < 0.01 
Figure 1 Scatterplots of the partial correlations between
reported 12 wk mean dietary fat intake (% of energy) and
changes in anthropometrics. (A) The relationship between MUFA
intake and change in % LM. (B) The relationship between MUFA
intake and the change in % BF. (C) The relationship between PUFA
intake and the percent change in WC.
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Page 7 of 10with the change in % BF (partial r = 0.49, P < 0.001)
(Figure 1B) accounting for 44 and 49 percent of the var-
iance in % LM and %BF, respectively. Reported 12 wk
mean dietary intake of % PUFA was positively associated
with the percent change in WC (partial r = 0.45 P <
0.01) (Figure 1C) accounting for 45% of the variance in
percent change in WC.
Discussion
Significant reductions in weight, WC, % BF and an
increase in % LM were found among all dietary treat-
ment groups in response to energy restriction. Dairy
product consumption was found to be significantly asso-
ciated with reduced WC and %BF; however, these rela-
tionships were no longer significant after adjustments
for protein and energy intakes and physical activity. Cir-
culating clinical and plasma lipidome values were not
significantly associated with time or treatment. Yet,
despite randomizing subjects into treatment groups the
dairy group had significantly higher levels of total FFA
at baseline compared with the calcium and placebo
groups. This relationship was significant despite adjust-
ments for age, site, sex, HOMA-IR, physical activity and
body composition. Nonetheless, plasma total FFA at 12
wk was not significantly different among the treatment
groups. Other confounding variables that could influ-
ence total FFA at baseline such as HOMA-IR, WC,
body composition, age, site and physical activity were
not significantly different among the treatment groups.
Based on dietary intake reported by subjects in weekly
diet records, the dairy group consumed more energy,
macronutrient and micronutrients such as calcium, bio-
tin, pantothenic acid, riboflavin, and vitamin D–com-
pared with the calcium supplement and placebo groups.
Calculated dietary intakes of energy and fat composition
were associated with changes in anthropometrics, but
not plasma lipidome after adjustment of sex. Some cau-
tion should be acknowledged regarding the possibility of
underreporting of food intake by obese subjects com-
pounded by nutrient specific underreporting by the gen-
eral population leading to unpredictable analytical
consequences [36]. Furthermore, underreporting may
affect the associations between dietary factors–specifi-
cally of n-6 polyunsaturated fats and fat from dairy pro-
ducts–and the metabolic syndrome suggesting
inaccurate dietary data can introduce spurious associa-
tions [37]. In addition, Nutritionist Pro has limitations
in the database for the estimation of dietary fat
composition.
In addition to consuming higher micro and macronu-
trients, the dairy group reported significantly higher
intake of SFA and lower intakes of MUFA and PUFA
compared with the calcium supplement and placebo
groups. Interestingly, the markers of dairy fats–myristic
(14:0), –pentadecanoic (15:0) and heptadecanoic acids
(17:0) [38,39] were not reflected in circulating plasma
lipids of the dairy treatment group. These discrepancies
are most likely due to the energy restrictive nature of
this study such that subjects in the dairy treatment
group were not consuming 3-4 servings of full fat dairy
products. In addition, heptadecanoic acid was not
included in our fatty acid output because it was one of
the internal standards used in the gas chromatography
analysis.
When expressed as a percent of total energy, dietary
fat composition was correlated with changes in anthro-
pometrics. Reported MUFA at 12wk was inversely and
positively associated with changes in % LM and % BF,
respectively. The observed associations between reported
MUFA intake and body composition support in vitro
studies that reported a positive relationship between adi-
pose growth and differentiation in response to oleic acid
incubation compared with various long-chain fatty acids
[40-42] and with varying concentrations of oleic acid
[42]. Unfortunately, the mechanistic relationships
between dietary MUFA intake on energy partitioning
and body composition in vivo is not well understood
and this study was not designed to assess causality.
R e p o r t e di n t a k e so fS F Aa n dP U F Aa t1 2w kw e r en o t
associated with changes in % LM, and % BF, yet PUFA
intake was positively associated with the % change in
WC. These data are corroborated by cross sectional stu-
dies in which PUFA intake was positively associated
with body mass index and waist-hip ratio in women
[43]. More specifically, intake of long chain omega 3
fatty acids were negatively associated with body fat [44]
and positively associated with fat oxidation [45] while
dietary omega 6 fatty acids was positively associated
with body fat [44]. In this study dietary n6:n3 was not
correlated with plasma lipids or changes in
anthropometrics.
Our findings were unlike a previous study in which
anthropometric changes were associated with dairy pro-
duct consumption in a subset of the population;
although adjustments for energy intake were not made
[46]. In order to determine if dairy product consump-
tion physiologically modulates body composition, several
study design criteria should be addressed. In our study,
the dietary treatment groups did not consume equal
amounts of protein–an independent variable associated
with changes in anthropometrics [47,48]. Second, there
were unequal number of males and females in each diet-
ary treatment which contributed to high inter-individual
variation known to influence changes in body composi-
tion [49]. Third, attrition rates among the intervention
sites were unequal which resulted in unequal number of
participants for each treatment group, hence introducing
variation associated with US geographical influences on
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Page 8 of 10habitual diet. Fourth, reported dietary intake in weekly
3-day diet records does not reliably assess dietary intake
[50,51]. Fifth, the sample size of our study was fairly
small unlike previous reports which identified relation-
ships between calcium intake and anthropometrics [4].
Sixth, individuals should have been randomized into
treatment groups not based on BMI or weight but by
metabolic phenotype such as insulin sensitivity and or
body composition to better control for metabolic
responses to dietary interventions. In addition, choosing
the statistical methodology for analyzing high density
data needs to be addressed. One of the challenges of
this study was the use of stepwise regression to identify
the relationships between diet and plasma lipids and
diet with changes in anthropometrics. There are limita-
tions with stepwise regression which include: bias in
overstating parameter estimation; risk of achieving a
type 1 error from multiple testing; reliance on over-fit-
ting final models [52]. Because plasma lipids are sub-
strates and products of shared metabolic pathways,
there will be collinearity. To address these limitations,
modeling in this study was guided under the current
understanding of lipid metabolism and diet rather than
random parameter selection. In addition, specific criteria
were used to ensure reliable model selection such as
Cook’s Distance, multi-collinearity testing and stringent
stepping method criteria with a F statistic probability for
entry (P < 0.01) and removal (P > 0.05) into the model.
Furthermore, this study was powered to determine the
change in body weight and not with respect to the rela-
tionship between changes in body composition and the
circulating lipidome. A null finding in this relationship
could be explained by the high inter-individual variation
in plasma lipid classes and thus would require a larger
sample size.
Conclusion
In summary, energy restriction for 12 weeks was asso-
ciated with changes in anthropometric measurements.
Unlike previous studies that found associations between
dairy product consumption and changes in anthropo-
metrics, this study was unable to detect associations
between dairy product consumption or calcium supple-
mentation and body composition. Yet, this study sup-
ports an important role of dietary fat composition on
changes in body composition during energy restriction.
Future large clinical trials designed to identify phenoty-
pic responses to diets differing in fat composition for
achieving metabolic regulation and beneficial changes to
body composition are warranted.
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